Qiagen Licenses Reagent Tech to Kreatech Biotechnology as It Plots More OEM Deals | GenomeWeb

Qiagen last week took another step towards making its technology broadly accessible to microarray users by announcing a non-exclusive licensing agreement with array manufacturer Kreatech Biotechnology.

The deal underscores Qiagen's strategy to leave the microarray reagent kit market for other players to compete in as it continues to invest in diagnostics and RT-PCR technologies, according to a company official.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.